<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295294</url>
  </required_header>
  <id_info>
    <org_study_id>15105</org_study_id>
    <secondary_id>2010-020922-16</secondary_id>
    <nct_id>NCT01295294</nct_id>
  </id_info>
  <brief_title>Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)</brief_title>
  <official_title>International, Prospective, Double-blind, 3-arm Comparative, Randomized, Placebo-controlled Phase IV Study on the Effect of Counseling and Either Tranexamic Acid or Mefenamic Acid or Placebo, on the Management of Bleeding/Spotting in Women Using the Levonorgestrel-releasing Intrauterine System (MIRENA) for Contraception.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate if the study drugs (tranexamic acid or mefenamic
      acid) can control irregular bleeding during the first 3 months of using Mirena. The study
      drugs tested are tested against placebo (&quot;dummy medication not containing any active drug&quot;).
      Treatment period is followed by a one-month period when study drugs are not taken but Mirena
      use is continued.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy variable will be the cumulative number of bleeding / spotting days</measure>
    <time_frame>During 90 day double-blind treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe and compare the bleeding patterns observed in women during treatment period</measure>
    <time_frame>90 day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe and compare the bleeding patterns observed in women during follow-up period</measure>
    <time_frame>During the 30 day follow-up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with oral blinded study drug treatment for bleeding / spotting</measure>
    <time_frame>90 day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of dysmenorrhea</measure>
    <time_frame>During 120 day study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuation rate with study drug</measure>
    <time_frame>During the 90 day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuation rate with Mirena</measure>
    <time_frame>During 120 day study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Collection</measure>
    <time_frame>Until day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of spotting-only days</measure>
    <time_frame>During the 90-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding / spotting episodes</measure>
    <time_frame>During the 90-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of bleeding / spotting episodes</measure>
    <time_frame>During the 90-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding days with heavy intensity</measure>
    <time_frame>During the 90-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of B/S days between Day 60 and Day 90 of MIRENA use and the 30-day follow-up period</measure>
    <time_frame>Up to day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with levonorgestrel-releasing intrauterine system</measure>
    <time_frame>Up to day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of pain medication for dysmenorrhea during the 90 day treatment period</measure>
    <time_frame>During the 90-day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding-only days</measure>
    <time_frame>During the 90-day treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">187</enrollment>
  <condition>Uterine Hemorrhage</condition>
  <arm_group>
    <arm_group_label>tranexamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with successful MIRENA insertion will receive treatments with tranexamic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mefenamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with successful MIRENA insertion will receive treatments with mefenamic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo + Mirena (Levonorgestrel IUS, BAY86-5028)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with successful MIRENA insertion will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <description>500 mg 3 times daily per oral during bleeding/spotting episodes</description>
    <arm_group_label>tranexamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mefenamic acid</intervention_name>
    <description>500 mg 3 times daily per oral during bleeding/spotting episodes</description>
    <arm_group_label>mefenamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 times daily per oral during bleeding/spotting episodes</description>
    <arm_group_label>placebo + Mirena (Levonorgestrel IUS, BAY86-5028)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirena (Levonorgestrel IUS, BAY86-5028)</intervention_name>
    <description>In vitro release rate 20 microgram/24 hours. Intrauterine system</description>
    <arm_group_label>tranexamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)</arm_group_label>
    <arm_group_label>mefenamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)</arm_group_label>
    <arm_group_label>placebo + Mirena (Levonorgestrel IUS, BAY86-5028)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Healthy female subjects requesting contraception

          -  Age: 18 - 45 years inclusive

          -  Successful interval insertion of MIRENA

          -  History of regular cyclic menstrual periods

          -  Normal or clinically insignificant cervical smear not requiring further follow up

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Climacteric symptoms prior to the screening visit

          -  Known or suspected clinically significant ovarian cysts, endometrial polyps, fibroids,
             or other genital organ pathology, that, in the opinion of the investigator, may
             interfere with the assessment of the bleeding profile during the study

          -  Undiagnosed abnormal genital bleeding

          -  Current or history of thrombembolic disease, or established risk factors for venous
             thromboembolism

          -  Current migraine, focal migraine with asymmetrical visual loss or other symptoms
             indicating transient cerebral ischemia, or exceptionally severe headaches

          -  Hypersensitivity to any ingredient of the investigational medicinal products or the
             non-investigational medicinal product

          -  Daily or frequent use of a nonsteroidal anti-inflammatory drug (NSAIDs) for any
             condition

          -  Not willing to use nonsteroidal anti-inflammatory drug (NSAIDs) medication as pain
             medication during the double blind treatment period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>København NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skive</city>
        <zip>DK-7800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Søborg</city>
        <zip>DK-2860</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ålborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Århus C</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mallow</city>
        <state>Cork</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blackrock</city>
        <state>Dublin</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elverum</city>
        <zip>2403</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haugesund</city>
        <zip>5507</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trondheim</city>
        <zip>7012</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Ireland</country>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here and search for websynopsis information of Bayer's products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu</url>
    <description>Click here and search for information of Bayer products for Europe</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2011</study_first_submitted>
  <study_first_submitted_qc>February 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2011</study_first_posted>
  <last_update_submitted>November 2, 2014</last_update_submitted>
  <last_update_submitted_qc>November 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine Hemorrhage</keyword>
  <keyword>Contraception</keyword>
  <keyword>Contraceptive Methods</keyword>
  <keyword>Intrauterine devices</keyword>
  <keyword>Mirena</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Mefenamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

